News

Yacktman Asset Management's Q2 2025 13F portfolio value dipped slightly to $7.44B. Click here to read more about the ...
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.
PNC Financial Services Group Inc. trimmed its Johnson & Johnson holdings by 0.5%, now controlling around 6 million shares.
Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...
Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...
Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
A phase 3, international, randomized clinical trial assessed the safety and efficacy of canagliflozin for treatment of type 2 diabetes mellitus (T2DM) in children and adolescents.
Johnson & Johnson witnessed a notable increase in interest from Private Advisory Group LLC, which upped its holdings by 61.8% ...
Johnson & Johnson (NYSE: JNJ) is one of the top cheap pharmaceutical stocks to buy now. On July 29, Johnson & Johnson ...
Johnson & Johnson is still facing many lawsuits that threaten its business. It may face additional challenges from patent ...
Johnson & Johnson JNJ and AstraZeneca AZN rank among the world’s largest pharmaceutical companies, each with a broad and ...